NEW YORK – Royalty Pharma has acquired the remaining royalty interest of PTC Therapeutics in Roche's spinal muscular atrophy drug Evrysdi (risdiplam) for up to $300 million, the company announced ...
The NDA is supported by data from a single-arm, multi-center, open-label, Phase II registration study in China that completed enrollment of 87 patients in March.
Stories about federal funding cuts, lab test regulation, and increasing adoption of DPYD testing were the most popular among readers.
The firm submitted non-clinical and clinical modules of its rolling BLA for DTX401 in August and has now submitted the chemistry, manufacturing, and controls module.
Below is a list of the 10 precision oncology stories that resonated most with readers during the year: 2. Mass General Brigham Becomes Latest US Health System to Adopt Pretreatment DPYD Testing 3. JP ...
NEW YORK – Senhwa Biosciences this week said that its investigational agent pidnarulex will be studied in combination with AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in ...
NEW YORK – Verastem Oncology is discontinuing a Phase I/II clinical trial evaluating its RAF/MEK inhibitor Avmapki (avutometinib) in combination with Amgen's KRAS G12C inhibitor Lumakras (sotorasib) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback